Tramadol

For adults with pain severe enough to require an opioid analgesic when alternative treatments are inadequate. Reserve treatment for patients for whom nonopioid alternatives are ineffective, not tolerated, or otherwise inadequate; addiction and overdose risks persist at recommended doses.

For adults with severe and persistent pain requiring opioid treatment that cannot be adequately treated with alternatives, including immediate-release opioids. ER is not an as-needed analgesic.

Neither selected product is approved for pediatric use. All children under 12 years, and patients under 18 years after tonsillectomy or adenoidectomy, are specifically contraindicated. Avoid use in adolescents with obesity, obstructive sleep apnea, or severe lung disease. Combination products and other ER delivery systems are outside this profile.

If rapid analgesia is unnecessary, the label starts at 25 mg/day, increasing the total by 25 mg every 3 days in divided doses to 100 mg/day (25 mg four times daily), then by 50 mg every 3 days to 200 mg/day (50 mg four times daily). After titration, 50–100 mg every 4–6 hours as needed may be used, with a 400 mg/day ceiling. A direct 50–100 mg start is reserved for selected patients needing rapid effect when benefits outweigh higher initial adverse-effect risk. Individual lower limits below take precedence.

Start the selected ER tablet at 100 mg once daily; titrate by 100 mg no more often than every 5 days, up to 300 mg/day. For an IR-to-ER conversion, calculate the 24-hour IR total and round down to the next lower 100 mg increment; some patients cannot be converted because of ER strength and dose limits. No established conversion ratio exists for other opioids: clinician-directed initiation and close reassessment are necessary.

IR may be taken without regard to food. Take ER once daily at a consistent time and with consistent regard to food; swallow whole with liquid, never cut, crush, chew, break, or dissolve. Do not add another tramadol-containing medicine. Do not abruptly stop or rapidly reduce treatment in a physically dependent patient: agree on an individualized taper, pain plan, and follow-up; slow or pause reductions for withdrawal.

Children under 12 years; patients under 18 years after tonsillectomy/adenoidectomy; significant respiratory depression; acute or severe bronchial asthma without monitoring or resuscitation resources; known or suspected GI obstruction including paralytic ileus; and concurrent MAOIs or use within 14 days. Both labels contraindicate tramadol hypersensitivity; the IR label additionally specifies other product components or opioids.

Both selected labels carry boxed warnings for addiction, abuse and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal; CYP interactions; ultrarapid metabolism and fatal pediatric respiratory depression; and concomitant benzodiazepines or other CNS depressants. Opioid REMS counseling applies. ER must remain intact to prevent uncontrolled delivery.

Common reactions include dizziness, nausea, constipation, headache, somnolence, vomiting, itching, sweating, and weakness. Serious reactions include respiratory depression, seizures, serotonin syndrome, severe allergy/skin reactions, hypotension, and electrolyte or glucose disturbances. Trial rates differ by formulation, dose, and population and should not be compared directly.

Fluoxetine, paroxetine, bupropion, and quinidine can raise parent tramadol while lowering M1: analgesia may fall or withdrawal appear, while seizure and serotonin risks rise. Stopping an inhibitor can increase M1 and respiratory depression; the label advises considering a lower tramadol dose and close monitoring.

Inhibitors such as erythromycin, azole antifungals, or ritonavir can increase exposure; consider dose reduction and monitor toxicity. Inducers such as rifampin or phenytoin can reduce effect or cause withdrawal; stopping an inducer can increase toxicity and may require dose reduction. Carbamazepine coadministration is not recommended because of reduced effect and seizure concerns.

SSRIs, SNRIs, TCAs, triptans and other serotonergic agents increase serotonin-syndrome risk; MAOIs are contraindicated within 14 days. Benzodiazepines, alcohol, other opioids, gabapentinoids and sedatives increase respiratory depression and death. Reserve necessary combinations for carefully selected patients at the lowest appropriate doses and durations, with close observation and overdose-reversal counseling.

Mixed agonist/antagonist or partial agonist opioids can reduce analgesia or precipitate withdrawal; coordinate care rather than independently stopping an opioid-use-disorder medicine. Muscle relaxants increase respiratory risk; anticholinergics increase retention/ileus risk. Monitor diuretic response, digoxin toxicity, and warfarin INR when relevant.

Human pregnancy data are insufficient to define drug-associated risk; animal findings support counseling about potential fetal harm. Prolonged use can cause neonatal opioid withdrawal; placental transfer can cause neonatal respiratory depression, and use during or immediately before labor is not recommended when alternatives are appropriate. Breastfeeding is not recommended during tramadol treatment because tramadol and M1 enter milk and may cause infant sedation or respiratory depression. Long-term opioid use may reduce fertility; reversibility is uncertain.

The selected labels establish no pediatric safety/effectiveness. Specific age contraindications and adolescent respiratory risk factors are listed above. Older or debilitated patients are more vulnerable to respiratory effects; IR patients over 75 years have a 300 mg/day ceiling. Monitor sedation, falls, sodium-related symptoms, and kidney function.

Use the IR adjustments in the dosing table. Hemodialysis removes only about 7% of a dose, and the adjusted usual IR dose may be given on dialysis days. Do not use the selected ER tablet when CrCl is below 30 mL/min or in severe hepatic impairment (Child-Pugh C); limited dose flexibility prevents safe adjustment.

Tramadol and its active O-desmethyl metabolite M1 contribute to analgesia. Opioid-receptor activity, including μ-receptor agonism, occurs alongside inhibition of norepinephrine and serotonin reuptake. These effects also explain respiratory depression and serotonin-related interaction risks.

IR absolute bioavailability

Approximately 75% after a 100 mg oral dose

IR peak concentrations

Parent about 2 hours; M1 about 3 hours

IR mean terminal half-lives

Parent 6.3 hours; M1 7.4 hours

Elimination

Hepatic metabolism; renal excretion of parent and metabolites

M1 formation depends on CYP2D6; CYP3A4 also contributes to metabolism. Kidney or liver impairment can prolong exposure. ER prolongs drug delivery and is not interchangeable dose-for-dose with arbitrary IR schedules; take it with consistent regard to food. Hemodialysis removes little tramadol or M1.

Reassess pain and function, sedation and respiration, misuse risk, constipation, interactions, and withdrawal at initiation, titration, conversion, and follow-up. Review kidney/liver status and seizure/mental-health history. Investigate symptomatic hyponatremia, hypoglycemia, adrenal insufficiency, dysphagia, or paradoxically worsening pain.

Do not share medication, add alcohol or sedatives, or drive until effects are known. Keep locked away from children and visitors. Discuss access to naloxone or nalmefene, recognize slow breathing or inability to awaken, and teach caregivers how to use the selected reversal product. Do not alter ER tablets, self-escalate doses, or abruptly stop treatment; use an authorized take-back option and follow the label’s disposal instructions.

Call emergency services immediately for suspected overdose; administer the available opioid reversal agent as directed while obtaining help. Reversal may not correct every tramadol effect, and seizures may occur; hospital airway support and observation are essential. ER can continue releasing drug for 24–48 hours or longer, so repeated reversal and prolonged monitoring may be needed. Dialysis is not an effective overdose-removal strategy.

Selected product

Tramadol HCl IR 50 mg · Preferred Pharmaceuticals

Appearance

White to off-white, film-coated, round

Imprint

7 and 2 separated by functional score; reverse plain

Example NDC

68788-4114-3 · bottle of 30

Selected IR product: 50 mg functionally scored tablet. Selected Lupin ER products: 100 mg (L010), 200 mg (L011), and 300 mg (L012), white to off-white coated tablets. Other manufacturers, ER capsules, oral liquids, and tramadol/acetaminophen combinations require their own label review.

IR: 20–25°C, excursions 15–30°C, in a tight container. Selected ER: 25°C, excursions 15–30°C. Store securely and use the product-specific disposal instructions. ER tablets must remain whole; a functional IR score does not authorize breaking an ER product.